Clinical Trial Details

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With Or Without Enhanced Anti-Androgen Therapy With Apalutamide In Recurrent Prostate Cancer (BALANCE*) *Biomarker trial of ApaLutamide and rAdiation for recurrent prostate CancEr (NRG-GU006)

This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer than radiation alone.

NRG-GU006

Learn More

Principal Investigator(s)

Sponsor(s)

NRG Oncology Group

Contact

Ed Hatton, RN at 203-358-8879 or [email protected]

Location

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.